Logo

Holoclara Inc..

Holoclara is an early stage therapeutic company founded by Caltech and Cornell scientists that are taking a novel approach to develop a new therapeutic class of drugs for patients with severe allergic or autoimmune disease.

Los Angeles, CA, USA

One Liner

One Liner
Holoclara is an early stage therapeutic company founded by Caltech and Cornell scientists that are taking a novel approach to develop a new therapeutic class of drugs for patients with severe allergic or autoimmune disease.

What Problem We are Solving

Problem
Hundreds of millions of people continue to suffer from allergic and autoimmune diseases. These diseases continue to rise despite the advancements of modern medicine, whereas other major diseases such as stroke, heart disease, and cancer have plateaued or declined. What these patients need is an entirely novel approach, rather than an incremental iteration on previous approaches. We are using a completely novel approach and are creating an entirely new class of therapeutics for these patients.

About Us

About Us
There are several approaches to designing therapies. One way is gene therapy, however there is no one faulty gene here. Targeted biologics are antibodies that target one inflammatory signal, but 30% of patients discontinue this therapy likely because that is insufficient to only target one cell signal when many are involved. Drug developers have yet to explore mining natural materials that are already known to have beneficial effects for these patients, the same way taxol was discovered and became the top selling drug for cancer patients. There are decades of studies showing that roundworms have profound therapeutic effects for these patients, but no one has succeeded in identifying their therapeutic components, until now.

Business Model

Business Model
Our model is to follow in the footsteps of drugs like Keytruda, Revlimib, and Opdivo, and take our lead molecule (which has broad therapeutic potential) and begin commercializing with the Orphan disease Eosinophilic Esophagitis, for which there is currently no FDA drug approved. The average annual cost for an orphan drug is $100,000. With 150K patients in the TAM, there is a $15B annual revenue. We will then expand into the 30% of patients of severe asthma that are discontinuing biologics, for which there is a TAM of 450K patients and an average drug price for this population being $30K annually, leading to $13B annual revenue.

Competitive Advantage

Quote
Our competitive advantage is that we have potent therapeutic effects that can help patients with severe disease, but do not have any known toxicities. We also target multiple inflammatory cell types rather that one, positioning us to outcompete biologics.

Revenue

Revenue To Date
N/A
MRR
N/A
Revenue YTD
N/A
Burn Rate
N/A

Customer Costs

CAC
N/A
LTV
N/A
Churn
N/A
Margins
N/A

Go-To Market Strategy

Business Strategy
If you look at Merck, BMS and J&J's top selling drugs in 2020 (Keytruda, Revlimib and Opdivo) their strategies have been to stack approvals for one segment of a patient population at a time. This allows for more targeted, successful clinical trials, year after year. We aim to take the same approach for allergic and autoimmune disease, knowing that there is great heterogeneity in these patients and that a piecemeal approach has led to the most successful revenue streams.

Team

Master Import
Master Import

CEO

Competitive Analysis

Competitive Analysys
The current competitive landscape for patients with severe allergic and autoimmune disease are steroids and biologics. Patients simply cannot take chronic steroids due to the side effects. Biologics like Humira are currently being used for patients with severe disease, but also come with significant side effect risks. The leading biologics in the asthma space target IL-5 or the receptor for IL-5, however 30% of patients are discontinuing therapy. Surveys show that the main reason is for insufficient control of disease. As such there is still a huge unmet need for these patients.

Competitor Website
x x
x x
x x

Networking

Networking
We are open to meeting up to grab a coffee, or just to chat. We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!

Share

Capital

Name Amount
Amount Raise To Date N/A
Investment Type N/A
Valuation
$19M

TAM SAM SOM

TAM
N/A
SAM
N/A
SOM
N/A

Business Stage

Business Stage
Seed